Severe azathioprine-induced myelotoxicity in a kidney transplant patient with thiopurine S-methyltransferase-deficient genotype (TPMT*3A/*3C)

Transplant International

Volumn 18, Issue 5, 2005, Pages 623-625

  Kurzawski, Mateusz ^a   Dziewanowski, Krzysztof ^b   Ciechanowski, Kazimierz ^a   Droździk, Marek ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b Department of General and Transplantation Surgery   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CEFUROXIME; COTRIMOXAZOLE; CYCLOSPORIN A; PREDNISONE; THIOPURINE METHYLTRANSFERASE; VERAPAMIL; IMMUNOSUPPRESSIVE AGENT; METHYLTRANSFERASE;

ACUTE GRAFT REJECTION; ANAMNESIS; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CHRONIC GLOMERULONEPHRITIS; DRUG DOSE REDUCTION; GENOTYPE; HOSPITAL DISCHARGE; HUMAN; KIDNEY TRANSPLANTATION; LABORATORY TEST; LETTER; PRIORITY JOURNAL; TREATMENT WITHDRAWAL; ADULT; BONE MARROW; CASE REPORT; DRUG EFFECT; ERYTHROCYTE COUNT; GENETICS; GLOMERULONEPHRITIS; LEUKOCYTE COUNT; MALE; METABOLISM; PHYSIOLOGY;

ADULT; AZATHIOPRINE; BONE MARROW; ERYTHROCYTE COUNT; GENOTYPE; GLOMERULONEPHRITIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LEUKOCYTE COUNT; MALE; METHYLTRANSFERASES;

EID: 23844546620     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2005.00095.x     Document Type: Letter

References (12)

1. Krynetski EY, Evans WE. Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms. Pharmacogenetics 1996; 6: 279.
2. Woodson LC, Dunnette JH, Weinshilboum RM. Pharmacogenetics of human thiopurine methyltransferase: kidney-erythrocyte correlation and immunotitration studies. J Pharmacol Exp Ther 1982; 222: 174.
3. McLeod HL, Lin J-S, Scott EP, et al. Thiopurine methyltransferase activity in American white subjects and black subjects. Clin Pharmacol Ther 1994; 55: 15.
4. Lennard L, Gibson BES, Nicole T, Lilleyman JS. Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia. Arch Dis Child 1993; 69: 577.
5. McLeod HL, Siva C. The thiopurine S-methyltransferase gene locus - implication for clinical pharmacogenomics. Pharmacogenomics 2002; 3: 89.
6. Kurzawski M, Droździk M, Gawronska-Szklarz B. Frequency distribution of thiopurine S-methyltransferase alleles in a Polish population. Ther Drug Monit 2004; 26: 541.
7. Evans WE, Hon YY, Bomgaars L, et al. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol 2001; 19: 2293.
8. Schutz E, Glimmert J, Mohr F, Oellerich M. Azathioprine induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient. Lancet 1993; 341: 436.
9. McBride KL, Gilchrist GS, Smithson WA, et al. Severe 6-thioguanine- induced marrow aplasia in a child with acute lymphoblastic leukemia and inhibited thiopurine methyltransferase deficiency. J Pediatr Hematol Oncol 2000; 22: 441.
10. McLeod HL, Coulthard S, Thomas AE, et al. Analysis of thiopurine methyltransferase variant alleles in childhood acute lymphoblastic leukaemia. Br Haem 1999; 105: 696.
11. Lennard L. Clinical implications of thiopurine methyltransferase - optimization of drug dosage and potential drug interactions. Ther Drug Monit 1998; 20: 527.
12. Evans WE. Pharmacogenetics of thiopurine S-methyltransferase and thiopurine therapy. Ther Drug Monit 2004; 26: 186.